Atara Biotherapeutics Inc (ATRA)

$0.5308

-0.01

(-2.59%)

Market is closed - opens 7 PM, 14 Jun 2024

Insights on Atara Biotherapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 957.0K → 27.35M (in $), with an average increase of 63.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -74.77M → -31.75M (in $), with an average increase of 28.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 81.8% return, outperforming this stock by 156.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.3% return, outperforming this stock by 335.5%

Performance

  • $0.51
    $0.54
    $0.53
    downward going graph

    3.3%

    Downside

    Day's Volatility :5.09%

    Upside

    1.85%

    downward going graph
  • $0.20
    $2.54
    $0.53
    downward going graph

    62.53%

    Downside

    52 Weeks Volatility :92.18%

    Upside

    79.13%

    downward going graph

Returns

PeriodAtara Biotherapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-18.31%
-0.3%
0.0%
6 Months
-19.63%
7.4%
0.0%
1 Year
-74.54%
11.0%
0.0%
3 Years
-96.28%
17.3%
-24.3%

Highlights

Market Capitalization
62.9M
Book Value
- $0.82
Earnings Per Share (EPS)
-2.12
PEG Ratio
0.0
Wall Street Target Price
4.17
Profit Margin
0.0%
Operating Margin TTM
-96.85%
Return On Assets TTM
-59.06%
Return On Equity TTM
-2014.86%
Revenue TTM
34.7M
Revenue Per Share TTM
0.3
Quarterly Revenue Growth YOY
2131.4%
Gross Profit TTM
63.6M
EBITDA
-215.8M
Diluted Eps TTM
-2.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.64
EPS Estimate Next Year
-0.66
EPS Estimate Current Quarter
-0.26
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    61%Buy
    30%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Atara Biotherapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
4
4
4
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 685.61%

Current $0.53
Target $4.17

Technicals Summary

Sell

Neutral

Buy

Atara Biotherapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
-2.07%
-19.63%
-74.54%
-96.28%
-97.53%
Moderna, Inc.
Moderna, Inc.
17.55%
87.94%
15.42%
-28.78%
814.11%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.19%
17.3%
33.92%
94.36%
234.29%
Novo Nordisk A/s
Novo Nordisk A/s
8.19%
44.85%
81.77%
239.36%
454.2%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.67%
17.46%
39.08%
144.25%
181.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
NA
NA
0.0
-0.64
-20.15
-0.59
NA
-0.82
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.82
29.82
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.58
49.58
2.36
3.48
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.23
31.23
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atara Biotherapeutics Inc
Atara Biotherapeutics Inc
Buy
$62.9M
-97.53%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$56.6B
814.11%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$111.3B
234.29%
29.82
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$636.1B
454.2%
49.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
181.72%
31.23
39.46%

Institutional Holdings

  • EcoR1 Capital, LLC

    8.44%
  • Redmile Group, LLC

    7.69%
  • BlackRock Inc

    5.89%
  • Vanguard Group Inc

    4.16%
  • T. Rowe Price Associates, Inc.

    4.12%
  • Boxer Capital LLC

    3.45%

Company Information

we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have

Organization
Atara Biotherapeutics Inc
Employees
173
CEO
Dr. Pascal Touchon D.V.M.
Industry
Health Technology

FAQs